Panbela therapeutics announces interim data analysis for aspire trial pushed to q1 2025

Trial's lower-than-expected event rate suggests improved survival outcomes trial's lower-than-expected event rate suggests improved survival outcomes

PBLA Ratings Summary

PBLA Quant Ranking